Notably, high NR2E3 expression emerged as a critical determinant correlated with favorable clinical outcomes, regardless of high expression levels of Sp1, β‐catenin, or p300, reinforcing NR2E3's role as a good prognostic indicator and tumor suppressor. The gene discussed is EP300; the disease is neoplasm.